Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6457296

Cc1cc(N[C@H]2CC[C@@H](NC(=O)Cc3ccc(F)c(F)c3)CC2)nc2ccccc12.O=C(O)C(F)(F)F

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.50
LMNA P02545 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
SIGMAR1 Q99720 2/20 0.48
RXFP1 Q9HBX9 2/20 0.45
USP2 O75604 1/20 0.44
MCHR1 Q99705 5/20 0.44
ADRA2A P08913 2/20 0.44
HTR1A P08908 1/20 0.44
ADRA1A P35348 1/20 0.44
HRH1 P35367 1/20 0.44
HTR2B P41595 1/20 0.44
NPY5R Q15761 1/20 0.44
SMYD3 Q9H7B4 2/20 0.40
GPR6 P46095 4/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7066893 1.00 KDM4E (0.50) KDM4ELMNASMN1; SMN2SIGMAR1RXFP1
SCHEMBL6455439 0.95 KDM4E (0.55) KDM4ELMNASMN1; SMN2SIGMAR1RXFP1
SCHEMBL6455435 0.95 KDM4E (0.55) KDM4ELMNASMN1; SMN2SIGMAR1RXFP1
Trifluoroacetic Acid SCHEMBL6457352 0.88 KDM4E (0.51) KDM4ELMNASMN1; SMN2MCHR1ADRA2A
Trifluoroacetic Acid SCHEMBL6462476 0.85 MCHR1 (0.61) KDM4ELMNASMN1; SMN2MCHR1ADRA2A
Trifluoroacetic Acid SCHEMBL6460104 0.81 MCHR1 (0.60) KDM4ELMNASMN1; SMN2RXFP1MCHR1
SCHEMBL6461515 0.80 MCHR1 (0.66) KDM4ELMNASMN1; SMN2MCHR1ADRA2A
SCHEMBL6461509 0.80 MCHR1 (0.66) KDM4ELMNASMN1; SMN2MCHR1ADRA2A
Trifluoroacetic Acid SCHEMBL6460864 0.80 LMNA (0.54) KDM4ELMNASMN1; SMN2RXFP1MCHR1
Hydrochloric Acid SCHEMBL6457539 0.79 MCHR1 (0.65) KDM4ELMNASMN1; SMN2MCHR1ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 KDM4E 1190/4885LMNA 3391/4885SMN1; SMN2 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.